Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
about
Update on the safety of second generation antipsychotics in youths: a call for collaboration among paediatricians and child psychiatristsCurrent Data on and Clinical Insights into the Treatment of First Episode Nonaffective Psychosis: A Comprehensive ReviewUsing Smartphone Apps to Promote Psychiatric and Physical Well-Being.Increased mortality in schizophrenia due to cardiovascular disease - a non-systematic review of epidemiology, possible causes, and interventions.Effects of second-generation antipsychotics on selected markers of one-carbon metabolism and metabolic syndrome components in first-episode schizophrenia patients.Body mass, cardiovascular risk and metabolic characteristics of young persons presenting for mental healthcare in Sydney, AustraliaEffects of antipsychotics, antidepressants and mood stabilizers on risk for physical diseases in people with schizophrenia, depression and bipolar disorder.Weight Gain and Its Correlates Among Forensic InpatientsSerum metabolite profile associates with the development of metabolic co-morbidities in first-episode psychosis.The effect of long-acting paliperidone palmitate once-monthly on negative and depressive symptoms in patients with schizophrenia switched from previous unsuccessful treatment with oral aripiprazole.Weight gain and antipsychotics: a drug safety review.Promoting physical health for people with schizophrenia by reducing disparities in medical and dental care.Diabetes and Schizophrenia.Who is responsible for metabolic screening for mental health clients taking antipsychotic medications?Evaluating an individualized lifestyle and life skills intervention to prevent antipsychotic-induced weight gain in first-episode psychosis.Incidence of non-alcoholic fatty liver disease and metabolic dysfunction in first episode schizophrenia and related psychotic disorders: a 3-year prospective randomized interventional study.Long-term metabolic effects of aripiprazole, ziprasidone and quetiapine: a pragmatic clinical trial in drug-naïve patients with a first-episode of non-affective psychosis.Progress towards parity: improving the physical health of long-term psychiatric inpatients.Cardiovascular Risk in Early Psychosis: Relationship with Inflammation and Clinical Features 6 Months after Diagnosis.The Wnt Signaling Pathway Effector TCF7L2 Mediates Olanzapine-Induced Weight Gain and Insulin Resistance.
P2860
Q26747123-1EAFCAF0-EC8B-4486-B674-6E37ADCB4727Q28079821-BC364FF9-ECA7-4100-AF82-8C10ADE14B09Q33442734-AF3A2DD0-5036-4701-8135-67FE2B858FBDQ34248044-4CA67FB4-F5F0-4C1A-854C-352666F8FC7FQ34484974-388B7978-4769-430C-AE85-822E0017304AQ35277878-1AB4D82E-0CA0-48C6-A35F-B8EEA78BBCB1Q35754726-6CCD488D-5B67-464A-81A9-68B7C280AF01Q35794607-0220C5D6-E1E0-4626-A5B7-307A92484EF2Q37648311-6ACA0756-98DA-4914-A6FC-894443DBDF12Q37649902-C690EBC2-A986-4B24-AC22-E10801921E94Q38268590-DA164C4A-03F1-4DD9-8D98-D1E671FFDD09Q38469831-3214CAF5-A5EF-4493-A102-95F0C47D5350Q38709352-55FD76F2-2A99-4A51-9A5A-98F7F6E1E43AQ39017478-D881B86C-1374-4CC1-9C0D-F308512C1CF0Q39035010-F5F7014A-2C5A-4F16-805F-0F6073AB2489Q40542879-ED89D7A1-D714-491C-9BAF-A4532DCE8FCDQ47587816-79E8F4C5-7943-430E-A8D0-816113405E15Q50627489-BABB85A4-CA88-40A5-BF2D-BE5252417386Q52755746-6F5443A9-348F-4FBC-8142-1BF0A815026EQ53689686-449994CA-5C51-4BE9-8AD5-6867EEA16D83
P2860
Course of weight gain and metabolic abnormalities in first treated episode of psychosis: the first year is a critical period for development of cardiovascular risk factors.
description
2013 nî lūn-bûn
@nan
2013年の論文
@ja
2013年学术文章
@wuu
2013年学术文章
@zh
2013年学术文章
@zh-cn
2013年学术文章
@zh-hans
2013年学术文章
@zh-my
2013年学术文章
@zh-sg
2013年學術文章
@yue
2013年學術文章
@zh-hant
name
Course of weight gain and meta ...... f cardiovascular risk factors.
@en
Course of weight gain and meta ...... f cardiovascular risk factors.
@nl
type
label
Course of weight gain and meta ...... f cardiovascular risk factors.
@en
Course of weight gain and meta ...... f cardiovascular risk factors.
@nl
prefLabel
Course of weight gain and meta ...... f cardiovascular risk factors.
@en
Course of weight gain and meta ...... f cardiovascular risk factors.
@nl
P2093
P2860
P1476
Course of weight gain and meta ...... f cardiovascular risk factors.
@en
P2093
Gema Pardo-Garcia
Jose Antonio Amado
M Teresa Garcia-Unzueta
Obdulia Martínez-García
Rafael Tabares-Seisdedos
Rocio Pérez-Iglesias
P2860
P356
10.1017/S1461145713001053
P577
2013-10-08T00:00:00Z